Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
Recent study shows oral semaglutide reduces cardiovascular risk in type 2 diabetes patients, enhancing diabetes and heart ...
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of ...
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...
News-Medical.Net on MSN4d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
According to BMO Capital Markets, Rybelsus’ outcomes in SOUL were “inconsistent,” failing to significantly lower ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback